SGP
SpyGlass Pharma, Inc. Common Stock
There isn't enough reported data to score SGP yet.
SGP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
SGP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
SGP PE Valuation
SGP has no meaningful PE right now: it lost money over the past year.
SGP Forward outlook
There aren't enough analyst estimates for SGP to show an outlook.
SGP Earnings Per Share
SGP Quarterly Revenue
SGP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$18.5M | -$9.5M |
SGP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +11.5K shares |
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
SGP Net Leverage
SGP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SGP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.1 | Neutral |
| Stochastic | 82.8 | Overbought |
SGP's weekly RSI is 64 (neutral) and its Stochastic is 83 (overbought).
SGP PE vs Healthcare Sector
SGP has no meaningful PE right now: it lost money over the past year.
SGP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.0 | 15% above |
| 20 week MA | $26.3 | 27% above |
SGP is in an uptrend: it's above all two of its weekly moving averages, and 27% above its 20-week average.
SGP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $26.4 | $33.3 | +26% |
It's up 26% so far in 2026.